search
Back to results

LRAMPS Versus LDP in Selected Early-stage Left-sided Pancreatic Cancer

Primary Purpose

Left-sided Pancreatic Cancer

Status
Not yet recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
LRAMPS
LDP
Sponsored by
Fudan University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Left-sided Pancreatic Cancer focused on measuring Left-sided pancreatic cancer, Early-stage tumor, Laparoscopic radical antegrade modular pancreatosplenectomy, Laparoscopic distal pancreatosplecnectomy, Surgical complication, Oncologic prognosis

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Clinically diagnosed as resectable left-sided pancreatic cancer before surgery. Imaging tumor diameter ≤ 4 cm. Located ≥ 1cm from the celiac trunk. Tumor didn't invade the fascial layer behind the pancreas. Be able to comply with research protocol. Voluntary participation and signed informed consent. Exclusion Criteria: Received neoadjuvant therapy. Presence of liver or other distant metastasis. Multifocal or recurrent disease. History of other malignancies. Simultaneously participating in other clinical trials.

Sites / Locations

  • Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

LRAMPS group

LDP group

Arm Description

Patients who meet the inclusion and exclusion criteria will undergo laparoscopic radical antegrade modular pancreatosplenectomy (LRAMPS) surgery.

Patients who meet the inclusion and exclusion criteria will undergo laparoscopic distal pancreatosplecnectomy (LDP) surgery.

Outcomes

Primary Outcome Measures

R0 retroperitoneal margin rate
R0 retroperitoneal margin rate diagnosed by postoperative pathological examination.
R0 transection margin rate
R0 transection margin rate diagnosed by postoperative pathological examination.
Lymph node positive rate
Lymph node positive rate diagnosed by postoperative pathological examination.

Secondary Outcome Measures

Perioperative complication rate
Adverse events that occur during or after the surgery, including the incidence of postoperative complications reported according to the Clavien-Dindo classification, clinical relevant postoperative pancreatic fistula (POPF), postoperative pancreatic hemorrhage (PPH), delayed gastric emptying (DGE), reoperation rate and mortality rate within 90 days after surgery.
Life quality satisfaction evaluated according to EORTC C30 scale
The patient's health-related quality of life after surgical intervention. It includes physical, emotional, and social aspects of a patient's well-being. This study evaluated quality of life using a telephone survey and the EORTC C30 scales.
Recurrence-free survival (RFS)
The time of surgery to the time of tumor recurrence or death.
Overall survival (OS)
The time from the surgery to death from any cause.

Full Information

First Posted
July 2, 2023
Last Updated
September 21, 2023
Sponsor
Fudan University
Collaborators
The Third Affiliated Hospital of Soochow University, Qilu Hospital of Shandong University
search

1. Study Identification

Unique Protocol Identification Number
NCT05939063
Brief Title
LRAMPS Versus LDP in Selected Early-stage Left-sided Pancreatic Cancer
Official Title
Laparoscopic Radical Antegrade Modular Pancreatosplenectomy Versus Laparoscopic Distal Pancreatosplecnectomy in Selected Left-sided Pancreatic Cancer: a Multicenter Randomized Controlled Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
October 1, 2023 (Anticipated)
Primary Completion Date
August 31, 2025 (Anticipated)
Study Completion Date
August 31, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fudan University
Collaborators
The Third Affiliated Hospital of Soochow University, Qilu Hospital of Shandong University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This multicenter randomized controlled clinical trial proposed the criteria for selecting patients with early-stage left-sided pancreatic cancer and aimed to compare the perioperative and oncological outcomes of patients within the criteria who underwent laparoscopic radical antegrade modular pancreatosplenectomy versus laparoscopic distal pancreatosplenectomy.
Detailed Description
Although prospective comparative studies are lacking, laparoscopic distal pancreatosplenectomy (LDP) was considered to be feasible, safe, and oncologically equivalent for treating pancreatic ductal adenocarcinoma (PDAC). However, the extent of posterior resection and the oncological safety of achieving complete N1 lymph node resection in LDP remain uncertain. Strasberg proposed radical antegrade modular pancreatosplenectomy (RAMPS) for the treatment of resectable left-sided PDAC and confirmed that this technique can achieve negative margins and satisfactory survival. Given the oncological equivalence of laparoscopic radical antegrade modular pancreatosplenectomy (LRAMPS) and its advantages in short-term outcomes, several studies have assessed the feasibility of LRAMPS as the standard treatment for resectable left-sided PDAC. However, previous studies on LRAMPS have mostly included tumors staged T2 and above, and there is currently no research on the routine use of LRAMPS for early-stage tumors. We proposed the criteria for selecting patients with early-stage left-sided PDAC: (1) diameter ≤ 4 cm; (2) located ≥ 1 cm from the celiac trunk; (3) didn't invade the fascial layer behind the pancreas. This multicenter open-label randomized controlled clinical trial aims to compare the perioperative and oncological outcomes of patients within the criteria who underwent LRAMPS versus LDP.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Left-sided Pancreatic Cancer
Keywords
Left-sided pancreatic cancer, Early-stage tumor, Laparoscopic radical antegrade modular pancreatosplenectomy, Laparoscopic distal pancreatosplecnectomy, Surgical complication, Oncologic prognosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
160 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
LRAMPS group
Arm Type
Active Comparator
Arm Description
Patients who meet the inclusion and exclusion criteria will undergo laparoscopic radical antegrade modular pancreatosplenectomy (LRAMPS) surgery.
Arm Title
LDP group
Arm Type
Experimental
Arm Description
Patients who meet the inclusion and exclusion criteria will undergo laparoscopic distal pancreatosplecnectomy (LDP) surgery.
Intervention Type
Procedure
Intervention Name(s)
LRAMPS
Intervention Description
For LRAMPS procedure, Gerota's fascia and perirenal fat capsule are removed, and the procedure is divided into anterior LRAMPS and posterior LRAMPS depending on whether the left adrenal gland is resected. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
Intervention Type
Procedure
Intervention Name(s)
LDP
Intervention Description
For LDP procedure, the dissection plane is located behind the fusion fascia. The N1 station lymph nodes (i.e., groups 10, 11, and 18) in the body and tail of the pancreas are removed. If the tumor is located near the pancreatic body, the No. 9 lymph node group is additionally removed.
Primary Outcome Measure Information:
Title
R0 retroperitoneal margin rate
Description
R0 retroperitoneal margin rate diagnosed by postoperative pathological examination.
Time Frame
From the date of surgery to 1 month after surgery.
Title
R0 transection margin rate
Description
R0 transection margin rate diagnosed by postoperative pathological examination.
Time Frame
From the date of surgery to 1 month after surgery.
Title
Lymph node positive rate
Description
Lymph node positive rate diagnosed by postoperative pathological examination.
Time Frame
From the date of surgery to 1 month after surgery.
Secondary Outcome Measure Information:
Title
Perioperative complication rate
Description
Adverse events that occur during or after the surgery, including the incidence of postoperative complications reported according to the Clavien-Dindo classification, clinical relevant postoperative pancreatic fistula (POPF), postoperative pancreatic hemorrhage (PPH), delayed gastric emptying (DGE), reoperation rate and mortality rate within 90 days after surgery.
Time Frame
Within 90 days after surgery.
Title
Life quality satisfaction evaluated according to EORTC C30 scale
Description
The patient's health-related quality of life after surgical intervention. It includes physical, emotional, and social aspects of a patient's well-being. This study evaluated quality of life using a telephone survey and the EORTC C30 scales.
Time Frame
Through study completion, an average of 3 year.
Title
Recurrence-free survival (RFS)
Description
The time of surgery to the time of tumor recurrence or death.
Time Frame
Through study completion, an average of 3 year.
Title
Overall survival (OS)
Description
The time from the surgery to death from any cause.
Time Frame
Through study completion, an average of 3 year.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinically diagnosed as resectable left-sided pancreatic cancer before surgery. Imaging tumor diameter ≤ 4 cm. Located ≥ 1cm from the celiac trunk. Tumor didn't invade the fascial layer behind the pancreas. Be able to comply with research protocol. Voluntary participation and signed informed consent. Exclusion Criteria: Received neoadjuvant therapy. Presence of liver or other distant metastasis. Multifocal or recurrent disease. History of other malignancies. Simultaneously participating in other clinical trials.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xianjun Yu, MD, PhD
Phone
+86-13801669875
Email
yuxianjun@fudanpci.org
First Name & Middle Initial & Last Name or Official Title & Degree
Zheng Li, MD
Phone
+86-18521097686
Email
lizheng@fudanpci.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xianjun Yu, MD, PhD
Organizational Affiliation
Fudan University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Xiaowu Xu, MD
Organizational Affiliation
Fudan University
Official's Role
Study Director
Facility Information:
Facility Name
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200032
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xianjun Yu, MD, PhD
Phone
+86-13801669875
Email
yuxianjun@fudanpci.org
First Name & Middle Initial & Last Name & Degree
Xianjun Yu, MD, PhD
First Name & Middle Initial & Last Name & Degree
Xiaowu Xu, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
30080726
Citation
de Rooij T, van Hilst J, van Santvoort H, Boerma D, van den Boezem P, Daams F, van Dam R, Dejong C, van Duyn E, Dijkgraaf M, van Eijck C, Festen S, Gerhards M, Groot Koerkamp B, de Hingh I, Kazemier G, Klaase J, de Kleine R, van Laarhoven C, Luyer M, Patijn G, Steenvoorde P, Suker M, Abu Hilal M, Busch O, Besselink M; Dutch Pancreatic Cancer Group. Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD): A Multicenter Patient-blinded Randomized Controlled Trial. Ann Surg. 2019 Jan;269(1):2-9. doi: 10.1097/SLA.0000000000002979.
Results Reference
background
PubMed Identifier
31567509
Citation
Asbun HJ, Moekotte AL, Vissers FL, Kunzler F, Cipriani F, Alseidi A, D'Angelica MI, Balduzzi A, Bassi C, Bjornsson B, Boggi U, Callery MP, Del Chiaro M, Coimbra FJ, Conrad C, Cook A, Coppola A, Dervenis C, Dokmak S, Edil BH, Edwin B, Giulianotti PC, Han HS, Hansen PD, van der Heijde N, van Hilst J, Hester CA, Hogg ME, Jarufe N, Jeyarajah DR, Keck T, Kim SC, Khatkov IE, Kokudo N, Kooby DA, Korrel M, de Leon FJ, Lluis N, Lof S, Machado MA, Demartines N, Martinie JB, Merchant NB, Molenaar IQ, Moravek C, Mou YP, Nakamura M, Nealon WH, Palanivelu C, Pessaux P, Pitt HA, Polanco PM, Primrose JN, Rawashdeh A, Sanford DE, Senthilnathan P, Shrikhande SV, Stauffer JA, Takaori K, Talamonti MS, Tang CN, Vollmer CM, Wakabayashi G, Walsh RM, Wang SE, Zinner MJ, Wolfgang CL, Zureikat AH, Zwart MJ, Conlon KC, Kendrick ML, Zeh HJ, Hilal MA, Besselink MG; International Study Group on Minimally Invasive Pancreas Surgery (I-MIPS). The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection. Ann Surg. 2020 Jan;271(1):1-14. doi: 10.1097/SLA.0000000000003590.
Results Reference
background
PubMed Identifier
29099399
Citation
van Hilst J, de Rooij T, Klompmaker S, Rawashdeh M, Aleotti F, Al-Sarireh B, Alseidi A, Ateeb Z, Balzano G, Berrevoet F, Bjornsson B, Boggi U, Busch OR, Butturini G, Casadei R, Del Chiaro M, Chikhladze S, Cipriani F, van Dam R, Damoli I, van Dieren S, Dokmak S, Edwin B, van Eijck C, Fabre JM, Falconi M, Farges O, Fernandez-Cruz L, Forgione A, Frigerio I, Fuks D, Gavazzi F, Gayet B, Giardino A, Groot Koerkamp B, Hackert T, Hassenpflug M, Kabir I, Keck T, Khatkov I, Kusar M, Lombardo C, Marchegiani G, Marshall R, Menon KV, Montorsi M, Orville M, de Pastena M, Pietrabissa A, Poves I, Primrose J, Pugliese R, Ricci C, Roberts K, Rosok B, Sahakyan MA, Sanchez-Cabus S, Sandstrom P, Scovel L, Solaini L, Soonawalla Z, Souche FR, Sutcliffe RP, Tiberio GA, Tomazic A, Troisi R, Wellner U, White S, Wittel UA, Zerbi A, Bassi C, Besselink MG, Abu Hilal M; European Consortium on Minimally Invasive Pancreatic Surgery (E-MIPS). Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA): A Pan-European Propensity Score Matched Study. Ann Surg. 2019 Jan;269(1):10-17. doi: 10.1097/SLA.0000000000002561.
Results Reference
background
PubMed Identifier
12773980
Citation
Strasberg SM, Drebin JA, Linehan D. Radical antegrade modular pancreatosplenectomy. Surgery. 2003 May;133(5):521-7. doi: 10.1067/msy.2003.146.
Results Reference
background
PubMed Identifier
17254928
Citation
Strasberg SM, Linehan DC, Hawkins WG. Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: ability to obtain negative tangential margins. J Am Coll Surg. 2007 Feb;204(2):244-9. doi: 10.1016/j.jamcollsurg.2006.11.002. Epub 2007 Jan 4.
Results Reference
background
PubMed Identifier
22192922
Citation
Mitchem JB, Hamilton N, Gao F, Hawkins WG, Linehan DC, Strasberg SM. Long-term results of resection of adenocarcinoma of the body and tail of the pancreas using radical antegrade modular pancreatosplenectomy procedure. J Am Coll Surg. 2012 Jan;214(1):46-52. doi: 10.1016/j.jamcollsurg.2011.10.008.
Results Reference
background
PubMed Identifier
36088222
Citation
Takahashi A, Mise Y, Watanabe G, Yoshioka R, Ono Y, Inoue Y, Ito H, Takahashi Y, Kawasaki S, Saiura A. Radical antegrade modular pancreatosplenectomy enhances local control of the disease in patients with left-sided pancreatic cancer. HPB (Oxford). 2023 Jan;25(1):37-44. doi: 10.1016/j.hpb.2022.08.004. Epub 2022 Aug 20.
Results Reference
background
PubMed Identifier
35577311
Citation
Tang W, Zhang YF, Zhao YF, Wei XF, Xiao H, Wu Q, Du CY, Qiu JG. Comparison of laparoscopic versus open radical antegrade modular pancreatosplenectomy for pancreatic cancer: A systematic review and meta-analysis. Int J Surg. 2022 Jul;103:106676. doi: 10.1016/j.ijsu.2022.106676. Epub 2022 May 13.
Results Reference
background
PubMed Identifier
33033915
Citation
Zhang H, Li Y, Liao Q, Xing C, Ding C, Zhang T, Guo J, Han X, Xu Q, Wu W, Zhao Y, Dai M. Comparison of minimal invasive versus open radical antegrade modular pancreatosplenectomy (RAMPS) for pancreatic ductal adenocarcinoma: a single center retrospective study. Surg Endosc. 2021 Jul;35(7):3763-3773. doi: 10.1007/s00464-020-07938-1. Epub 2020 Oct 8.
Results Reference
background
PubMed Identifier
34609574
Citation
Wu EJ, Kabir T, Zhao JJ, Goh BKP. Minimally Invasive Versus Open Radical Antegrade Modular Pancreatosplenectomy: A Meta-Analysis. World J Surg. 2022 Jan;46(1):235-245. doi: 10.1007/s00268-021-06328-5. Epub 2021 Oct 5.
Results Reference
background
PubMed Identifier
24853839
Citation
Lee SH, Kang CM, Hwang HK, Choi SH, Lee WJ, Chi HS. Minimally invasive RAMPS in well-selected left-sided pancreatic cancer within Yonsei criteria: long-term (>median 3 years) oncologic outcomes. Surg Endosc. 2014 Oct;28(10):2848-55. doi: 10.1007/s00464-014-3537-3. Epub 2014 May 23.
Results Reference
background
PubMed Identifier
37249638
Citation
Sato S, Oba A, Kato T, Kobayashi K, Wu YHA, Ono Y, Sato T, Ito H, Inoue Y, Takahashi Y. Feasibility of laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) as a standard treatment for distal resectable pancreatic cancer. Langenbecks Arch Surg. 2023 May 30;408(1):217. doi: 10.1007/s00423-023-02942-0.
Results Reference
background
PubMed Identifier
35403874
Citation
Sutton TL, Potter KC, Mayo SC, Pommier R, Gilbert EW, Sheppard BC. Complications in Distal Pancreatectomy versus Radical Antegrade Modular Pancreatosplenectomy: A Disease Risk Score Analysis Utilizing National Surgical Quality Improvement Project Data. World J Surg. 2022 Jul;46(7):1768-1775. doi: 10.1007/s00268-022-06545-6. Epub 2022 Apr 11.
Results Reference
background
PubMed Identifier
30790046
Citation
Sivasanker M, Desouza A, Bhandare M, Chaudhari V, Goel M, Shrikhande SV. Radical antegrade modular pancreatosplenectomy for all pancreatic body and tail tumors: rationale and results. Langenbecks Arch Surg. 2019 Mar;404(2):183-190. doi: 10.1007/s00423-019-01763-4. Epub 2019 Feb 21.
Results Reference
background

Learn more about this trial

LRAMPS Versus LDP in Selected Early-stage Left-sided Pancreatic Cancer

We'll reach out to this number within 24 hrs